543 related articles for article (PubMed ID: 20036110)
1. Lymphangiogenesis and lymphatic metastasis in breast cancer.
Ran S; Volk L; Hall K; Flister MJ
Pathophysiology; 2010 Sep; 17(4):229-51. PubMed ID: 20036110
[TBL] [Abstract][Full Text] [Related]
2. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
3. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
[TBL] [Abstract][Full Text] [Related]
4. 3-O-Acetyloleanolic acid inhibits VEGF-A-induced lymphangiogenesis and lymph node metastasis in an oral cancer sentinel lymph node animal model.
Hwang-Bo J; Bae MG; Park JH; Chung IS
BMC Cancer; 2018 Jul; 18(1):714. PubMed ID: 29976150
[TBL] [Abstract][Full Text] [Related]
5. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis.
Wong SY; Haack H; Crowley D; Barry M; Bronson RT; Hynes RO
Cancer Res; 2005 Nov; 65(21):9789-98. PubMed ID: 16267000
[TBL] [Abstract][Full Text] [Related]
6. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
[TBL] [Abstract][Full Text] [Related]
7. Tumor and lymph node lymphangiogenesis--impact on cancer metastasis.
Tobler NE; Detmar M
J Leukoc Biol; 2006 Oct; 80(4):691-6. PubMed ID: 16793912
[TBL] [Abstract][Full Text] [Related]
8. From tumor lymphangiogenesis to lymphvascular niche.
Hirakawa S
Cancer Sci; 2009 Jun; 100(6):983-9. PubMed ID: 19385973
[TBL] [Abstract][Full Text] [Related]
9. Pathways targeting tumor lymphangiogenesis.
Wissmann C; Detmar M
Clin Cancer Res; 2006 Dec; 12(23):6865-8. PubMed ID: 17145802
[TBL] [Abstract][Full Text] [Related]
10. Interaction of tumor cells and lymphatic vessels in cancer progression.
Alitalo A; Detmar M
Oncogene; 2012 Oct; 31(42):4499-508. PubMed ID: 22179834
[TBL] [Abstract][Full Text] [Related]
11. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
[TBL] [Abstract][Full Text] [Related]
12. IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma.
Zhao W; Wang J; Zhu B; Duan Y; Chen F; Nian W; Sun J; Zhang B; Tong Z; Chen Z
Oncol Rep; 2016 Mar; 35(3):1483-92. PubMed ID: 26706909
[TBL] [Abstract][Full Text] [Related]
13. Tumor-induced lymphangiogenesis: a target for cancer therapy?
Thiele W; Sleeman JP
J Biotechnol; 2006 Jun; 124(1):224-41. PubMed ID: 16497404
[TBL] [Abstract][Full Text] [Related]
14. Lymphangiogenic growth factors, receptors and therapies.
Lohela M; Saaristo A; Veikkola T; Alitalo K
Thromb Haemost; 2003 Aug; 90(2):167-84. PubMed ID: 12888864
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels.
He Y; Rajantie I; Pajusola K; Jeltsch M; Holopainen T; Yla-Herttuala S; Harding T; Jooss K; Takahashi T; Alitalo K
Cancer Res; 2005 Jun; 65(11):4739-46. PubMed ID: 15930292
[TBL] [Abstract][Full Text] [Related]
16. Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer.
Lala PK; Nandi P; Majumder M
Cancer Metastasis Rev; 2018 Sep; 37(2-3):369-384. PubMed ID: 29858743
[TBL] [Abstract][Full Text] [Related]
17. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
18. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
[TBL] [Abstract][Full Text] [Related]
19. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis.
Hirakawa S; Kodama S; Kunstfeld R; Kajiya K; Brown LF; Detmar M
J Exp Med; 2005 Apr; 201(7):1089-99. PubMed ID: 15809353
[TBL] [Abstract][Full Text] [Related]
20. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis.
Lahdenranta J; Hagendoorn J; Padera TP; Hoshida T; Nelson G; Kashiwagi S; Jain RK; Fukumura D
Cancer Res; 2009 Apr; 69(7):2801-8. PubMed ID: 19318557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
